Oncology Current Ratio from 2010 to 2024

TOI Stock  USD 0.53  0.02  3.64%   
Oncology Institute's Current Ratio is increasing with slightly volatile movements from year to year. Current Ratio is predicted to flatten to 2.61. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
4.12478441
Current Value
2.61
Quarterly Volatility
1.26209131
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology main balance sheet or income statement drivers, such as Depreciation And Amortization of 3 M, Interest Expense of 7.1 M or Selling General Administrative of 121.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.44, Dividend Yield of 0.0235 or PTB Ratio of 2.51. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
This module can also supplement various Oncology Institute Technical models . Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

Latest Oncology Institute's Current Ratio Growth Pattern

Below is the plot of the Current Ratio of Oncology Institute over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Oncology Institute's Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 3.11 X10 Years Trend
Slightly volatile
   Current Ratio   
       Timeline  

Oncology Current Ratio Regression Statistics

Arithmetic Mean2.22
Geometric Mean1.98
Coefficient Of Variation56.75
Mean Deviation0.98
Median1.60
Standard Deviation1.26
Sample Variance1.59
Range4.1311
R-Value0.61
Mean Square Error1.07
R-Squared0.38
Significance0.01
Slope0.17
Total Sum of Squares22.30

Oncology Current Ratio History

2024 2.61
2023 4.12
2022 4.37
2021 5.17
2020 1.04

About Oncology Institute Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Oncology Institute income statement, its balance sheet, and the statement of cash flows. Oncology Institute investors use historical funamental indicators, such as Oncology Institute's Current Ratio, to determine how well the company is positioned to perform in the future. Although Oncology Institute investors may use each financial statement separately, they are all related. The changes in Oncology Institute's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Oncology Institute's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Oncology Institute Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Oncology Institute. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Ratio 4.12  2.61 

Currently Active Assets on Macroaxis

When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Oncology Stock analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Is Oncology Institute's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Revenue Per Share
4.635
Quarterly Revenue Growth
0.242
Return On Assets
(0.18)
Return On Equity
(1.04)
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.